Articles in this database are automatically generated by our AI system based on data from the Digicomply APP. While we strive for accuracy, the articles may not contain complete or verified information and are intended for informational purposes only. For accurate and reliable information, we recommend using SGS Digicomply or consulting verified sources and experts. All content is copyrighted; please credit SGS Digicomply (digicomply.com) when sharing.
On July 1, 2025, quality assurance issues were identified concerning the screening processes that determine donor eligibility and ensure compliance with the requirements of subpart C related to donor eligibility for biologics. This incident, categorized under control, was reported by the U.S. Food and Drug Administration, highlighting inadvertent deviations in the screening procedures.
The screening procedures are critical in maintaining the safety and efficacy of biologics, which rely on the quality of donor eligibility assessments. The identification of these quality assurance issues raises concerns regarding adherence to established regulatory standards that govern the biological product industry.
The origin of the issue is traced back to the United States, where regulatory frameworks are in place to oversee the rigorous processes involved in donor screening for biologics. Ensuring compliance with these requirements is essential for upholding public health standards and maintaining trust in the biological products available in the market.
This incident underscores the importance of continuous monitoring and evaluation of quality assurance systems to prevent inadvertent deviations that could compromise the integrity of donor eligibility screening. The involvement of the U.S. Food and Drug Administration in addressing these issues reflects the commitment to maintaining high standards in the biologics sector.
- Incident: Quality Assurance Issues has been detected in Screening determining donor eligibility and complying with all other requirements of subpart c donor eligibility biologics.
- Date: 2025-07-01
- Product: Screening determining donor eligibility and complying with all other requirements of subpart c donor eligibility biologics
- Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
- Origin of issue: United States of America
- Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
- Incident Category: Control
- Hazard Category: Inadvertent Deviations
- Source: U.S. Food and Drug Administration
For more detailed information about this and other similar incidents, with access to filtering options, historical data, and trend analysis, try the SGS Digicomply Food Safety Software.
Explore SGS Digicomply Food Safety Intelligence Hub demos here. (for enterprises only, no individual plans)
